AstraZeneca Pharma India Limited Earnings Summary — Q1 FY2027
AstraZeneca India Delivers 30% Revenue Growth Led by Rare Disease and Oncology Portfolio Expansion
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue grew 18.0% sequentially in Q1 FY2027.
- Revenue of ₹683 Cr is 29.7% higher year-on-year.
- Revenue has compounded at 29.3% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit of ₹38 Cr is 32.1% below the same quarter last year.
- Profit growth is trailing revenue growth this quarter.
- Net profit has compounded at -2.0% annualised across the period.
- Operating margin stands at 7.2% in Q1 FY2027.
- Operating margin compressed by 824 bps year-on-year.
- Over the last two years operating margin has contracted by 265 bps.
- PBT margin is 7.4%.
- Expenses grew 42.4% against revenue growth of 29.7%.
- Operating profit of ₹49 Cr is 39.7% lower year-on-year.
- Operating leverage has been under pressure recently.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 47/100 (Moderate) on the latest 10 quarters.
- Business momentum has softened and warrants monitoring.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 683 | 579 | 612 | 559 | 526 | 480 | 440 | 408 | 388 | 383 |
| Expenses | Improving | 634 | 518 | 567 | 484 | 445 | 394 | 363 | 355 | 349 | 334 |
| Operating Profit | Improving | 49 | 61 | 45 | 75 | 81 | 86 | 77 | 53 | 38 | 49 |
| Operating Margin | Stable | 7.2% | 10.5% | 7.3% | 13.4% | 15.4% | 18.0% | 17.5% | 12.9% | 9.8% | 12.9% |
| Other Income | Volatile | 9 | 5 | 7 | 1 | 11 | 10 | -26 | 8 | -49 | 9 |
| Interest | Improving | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | -0 |
| Depreciation | Volatile | 5 | 6 | 4 | 3 | 17 | 18 | 9 | 9 | 4 | 4 |
| Profit Before Tax | Volatile | 51 | 58 | 47 | 73 | 75 | 78 | 42 | 51 | -15 | 54 |
| Tax | Volatile | 13 | 13 | 14 | 19 | 19 | 20 | 11 | 13 | -3 | 15 |
| Net Profit | Volatile | 38 | 45 | 33 | 54 | 56 | 58 | 31 | 38 | -12 | 39 |
| Net Margin | Volatile | 5.6% | 7.8% | 5.3% | 9.7% | 10.6% | 12.1% | 7.0% | 9.4% | -3.0% | 10.3% |
Key Takeaways
- Revenue from operations grew by 30% YoY to INR 6,828 Mn, continuing a double-digit growth trajectory.
- The Rare Disease segment saw explosive growth, increasing 35-fold YoY to INR 144 Mn.
- Biopharmaceuticals (CVRM, R&I) demonstrated strong momentum with 36% growth reaching INR 1,619 Mn.
- Oncology remains the largest segment at INR 4,649 Mn, accounting for roughly 68% of total quarterly revenue.
- Achieved significant regulatory milestones for Acalabrutinib and Trastuzumab deruxtecan in Leukemia and Breast Cancer respectively.
- Strategic shift in leadership announced with Mr. Arun Krishna appointed as Additional Director and Ms. Bhavana Agrawal transitioning to a Non-Executive role.
Management Guidance
Management remains focused on investing strategically in opportunities that support sustainable long-term value creation, emphasizing expansion of access to life-changing medicines across India.
Sentiment Shift
Improving
The massive acceleration in the Rare Disease segment and consistent 30% top-line growth indicates successful penetration of the high-value specialty portfolio.
Outlook
The company expects to continue its growth momentum through scientific leadership, earlier diagnosis initiatives like the AI-enabled lung cancer screening MoU, and broadening the reach of its CVRM and oncology drugs.
From the Annual Report (Key Quotes)
“Our focus remains on investing strategically in opportunities that support sustainable long-term value creation.”
“The growth and momentum in the first quarter reflects the strength of our portfolio and focus on expanding access to serve more patients in India.”
“This performance builds on our strong track record of delivering a consistent double-digit growth over the last five years.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from AstraZeneca Pharma India Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.